Lv420
450 积分 2023-09-09 加入
First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
59分钟前
已完结
Biodistribution and preclinical safety profile of legubicin: A novel conjugate of doxorubicin and a legumain‐cleavable peptide linker
21天前
已完结
Targeted therapy
1个月前
已完结
Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies
1个月前
已完结
Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors
1个月前
已完结
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
1个月前
已完结
Clinical development of IDH1 inhibitors for cancer therapy
1个月前
已完结
The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Patients With Atopic Dermatitis: Randomized, Double-Blind, Phase 2 Proof of Concept Study
1个月前
已完结
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
1个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
1个月前
已完结
皖公网安备34019202002308
